CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for Mary Bauer
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.69 - 3.22
Open     -
Vol / Avg. 0.00/1.56M
Mkt cap 308.21M
P/E     -
Div/yield     -
EPS -0.59
Shares 180.24M
Beta 1.36
Inst. own 35%
Aug 3, 2015
Q2 2015 CTi Biopharma Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 6, 2015
Q1 2015 CTi Biopharma Corp Earnings Call - Webcast
May 6, 2015
Q1 2015 CTi Biopharma Corp Earnings Release
Mar 12, 2015
Q4 2014 CTi Biopharma Corp Earnings Call - Webcast
Mar 12, 2015
Q4 2014 CTi Biopharma Corp Earnings Release
Mar 9, 2015
CTI BioPharma & Baxter International Inc Conference Call to Discuss Clinical Trial - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1058.83% -156.85%
Operating margin -1007.44% -143.54%
EBITD margin - -105.32%
Return on average assets -149.15% -101.32%
Return on average equity -385.96% -220.85%
Employees 125 -
CDP Score - -


3101 Western Ave Ste 600
SEATTLE, WA 98121-3047
United States - Map
+1-206-2827100 (Phone)
+1-206-2846206 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company’s product Pixantrone (PIXUVRI) is a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. The Company’s pipeline products are Tosedostat, an oral aminopeptidase inhibitor that has demonstrated significant responses in patients with Acute Myeloid Leukemia (AML); Paclitaxel Poliglumex (Opaxio), a biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity; and Pacritinib, is an oral tyrosine kinase inhibitor with dual activity against Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase (also known as FLT3), which demonstrated meaningful clinical benefit and good tolerability in myelofibrosis patients in Phase 2 clinical trials.

Officers and directors

Phillip M. Nudelman Ph.D. Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
James A. Bianco M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Louis A. Bianco Executive Vice President, Finance and Administration, and Chief Governance Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack W. Singer M.D. Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.
Age: 71
Bio & Compensation  - Reuters
Matthew J. Plunkett Ph.D. Executive Vice President, Corporate Development
Age: 42
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 47
Bio & Compensation  - Reuters
Karen Ignagni Director
Age: 60
Bio & Compensation  - Reuters
John H. Bauer Independent Director
Age: 73
Bio & Compensation  - Reuters
Vartan Gregorian Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters